Specifically, siRNAs were applied to LN-18 and T98G glioma cell lines exhibiting high LIMD1-AS1 expression levels, while an overexpression plasmid was used in low-expressing LIMD1-AS1 SF126 glioma cells (Figs. 2K, 3A). This evidence concerns the gene LIMD1 and central nervous system cancer.